```html

Fever of Malaria – A Complete Patient‑Focused Guide

Overview

Malaria is an infectious disease caused by Plasmodium parasites that are transmitted to humans through the bite of an infected female Anopheles mosquito. A high‑grade fever is the hallmark of the disease and often the first symptom that brings a patient to medical attention, so the phrase “fever of malaria” is commonly used to describe the acute febrile phase.

Who it affects: Anyone living in or traveling to malaria‑endemic areas is at risk, but children under five and pregnant women are especially vulnerable because their immune systems are less able to control the infection.

Global prevalence: According to the World Health Organization (WHO), there were an estimated 241 million malaria cases and 627 000 deaths worldwide in 2020, most of them in sub‑Saharan Africa (≈95 % of deaths) <sup>[1]</sup>. In non‑endemic countries, malaria is rare but can occur in travelers returning from endemic regions, with ~10 000–15 000 imported cases reported annually in the United States <sup>[2]</sup>.

Symptoms

Malaria’s clinical presentation varies with the species of Plasmodium and the patient’s immunity. The fever pattern (every 48 h, 72 h, or irregular) is classic but not always present, especially in severe disease.

• Fever – sudden onset of high temperature (often >38.5 °C / 101.3 °F). May be cyclic (every 48–72 h) in P. vivax and P. ovale, or irregular in P. falciparum.
• Chills and rigors – intense shivering that precedes the fever spike.
• Headache – often described as throbbing and diffuse.
• Generalized malaise & fatigue – profound weakness that may last weeks after parasite clearance.
• Myalgia and arthralgia – muscle and joint aches.
• Nausea, vomiting, and loss of appetite.
• Diarrhea or abdominal pain – more common with P. falciparum.
• Sweats – profuse sweating as the fever breaks.
• Enlarged spleen (splenomegaly) – noted on physical exam in chronic or repeated infections.
• Cerebral symptoms – confusion, seizures, or coma (sign of severe malaria, usually P. falciparum).
• Jaundice – yellowing of the skin/eyes due to hemolysis.
• Dark urine – from hemoglobinuria in severe disease.

Causes and Risk Factors

Malaria results from infection with one of five Plasmodium species that infect humans:

• P. falciparum – most lethal, common in sub‑Saharan Africa.
• P. vivax – widespread in Asia & Latin America; known for dormant liver stages (hypnozoites).
• P. ovale – similar to P. vivax, mainly in West Africa.
• P. malariae – causes low‑grade, chronic infections.
• P. knowlesi – zoonotic, found in Southeast Asia.

Key risk factors

• Travel to or residence in endemic regions (especially rural areas near standing water).
• Lack of proper mosquito protection (insecticide‑treated bed nets, indoor residual spraying).
• Pregnancy – hormonal changes reduce immunity; parasites can cross the placenta.
• Young age – children’s immune responses are not fully developed.
• Immunosuppression – HIV infection, chemotherapy, or corticosteroid use.
• Genetic factors – sickle‑cell trait confers partial protection; lack of it increases susceptibility.

Diagnosis

Prompt diagnosis is critical because delayed treatment, especially of P. falciparum, can be fatal.

Laboratory tests

• Rapid Diagnostic Test (RDT) – detects parasite antigens in a finger‑stick blood sample. Gives results in 15–20 minutes and is widely used in field settings.
• Microscopy (thick and thin blood smears) – gold standard. Thick smear improves detection sensitivity; thin smear identifies species and parasite density (parasites/µL). Requires trained personnel.
• Polymerase Chain Reaction (PCR) – highly sensitive; used when species identification is difficult or for research.
• Complete blood count (CBC) – often shows anemia, thrombocytopenia, or leukopenia.
• Liver and renal function tests – assess organ involvement in severe disease.

Clinical criteria

In endemic areas, a fever + recent travel + positive RDT is sufficient to start treatment while awaiting confirmatory microscopy.

Treatment Options

Treatment depends on the infecting species, disease severity, patient age, pregnancy status, and local drug‑resistance patterns. WHO recommends artemisinin‑based combination therapy (ACT) for uncomplicated P. falciparum malaria.

Uncomplicated malaria

• Artemether‑lumefantrine (Coartem) – 3‑day oral regimen, widely used worldwide.
• Artesunate‑amodiaquine, Dihydroartemisinin‑piperaquine – alternatives where ACT resistance is low.
• Chloroquine – still effective for P. vivax, P. ovale, and P. malariae in many regions; resistance is common in P. falciparum.
• Primaquine – single‑dose (or 14‑day) therapy to eradicate liver hypnozoites of P. vivax and P. ovale. Must screen for G6PD deficiency first.

Severe (complicated) malaria

• Intravenous (IV) artesunate – recommended first‑line; reduces mortality by ~35 % compared with quinine.
• Supportive care: IV fluids, blood transfusion for severe anemia, renal replacement therapy if acute kidney injury, antipyretics, and seizure control.
• After IV artesunate, patients are switched to a full ACT oral regimen to complete therapy.

Lifestyle and supportive measures

• Fever control – acetaminophen (paracetamol) 500‑1000 mg every 6 h; avoid aspirin in children (risk of Reye’s syndrome).
• Hydration – oral rehydration solutions or IV fluids if vomiting.
• Rest and nutrition – high‑protein foods help rebuild red blood cells.

Living with Fever of Malaria

Even after parasite clearance, many patients experience lingering fatigue and anemia. Here are practical tips for daily management:

• Monitor temperature – keep a log; seek care if fever >39 °C (102 °F) persists >48 h after treatment.
• Stay hydrated – aim for at least 2–3 L of fluid daily unless contraindicated.
• Nutritious diet – iron‑rich foods (lean meat, beans, leafy greens) but discuss supplementation with a clinician if you have hemolysis.
• Gradual return to activity – avoid strenuous exercise for 1–2 weeks; listen to your body.
• Follow‑up labs – repeat blood smear 24‑48 h after treatment to confirm parasite clearance; CBC checks for anemia.
• Medication adherence – complete the full course, even if you feel better.
• Pregnancy considerations – continue antenatal visits; malaria can cause low birth weight and preterm delivery.

Prevention

Prevention combines personal protection, chemoprophylaxis, and community measures.

Personal protection

• Use insecticide‑treated bed nets (ITNs) every night.
• Apply EPA‑registered DEET, picaridin, or IR3535 repellents to exposed skin.
• Wear long‑sleeved shirts and pants, especially at dusk and dawn.
• Stay in screened or air‑conditioned rooms; use indoor residual spraying where available.

Chemoprophylaxis for travelers

Drug	Regimen	Key notes
Atovaquone‑proguanil (Malarone)	One tablet daily; start 1–2 days before travel, continue 7 days after leaving	Well tolerated; contraindicated in severe renal disease.
Doxycycline	100 mg daily; start 1–2 days before travel, continue 4 weeks after	Photosensitivity; avoid in pregnancy.
MEF (Mefloquine)	250 mg weekly; start ≥2 weeks before travel, continue 4 weeks after	Neuropsychiatric side effects; not for those with seizure disorders.

Community‑level interventions

• Mass drug administration (MDA) in high‑transmission zones.
• Larval source management – draining stagnant water, larviciding.
• Vaccination – RTS,S/AS01 (Mosquirix) approved for children in selected African countries; efficacy ~30 % against clinical malaria <sup>[3]</sup>.

Complications

If untreated or poorly treated, malaria can be life‑threatening.

• Cerebral malaria – seizures, coma, neurological deficits; mortality up to 20 % even with treatment.
• Severe anemia – hemoglobin <7 g/dL common in children; may require transfusion.
• Acute respiratory distress syndrome (ARDS).
• Acute kidney injury – oliguria or anuria.
• Hypoglycemia – especially with quinine therapy or in pregnant women.
• Hemoglobinuria & blackwater fever – massive hemolysis leading to dark urine.
• Placental malaria – causes low birth weight, stillbirth, maternal anemia.
• Post‑malaria neurological syndrome – delayed neurocognitive deficits after recovery.

When to Seek Emergency Care

References

1. World Health Organization. World Malaria Report 2022. Geneva: WHO; 2022.
2. Centers for Disease Control and Prevention. Malaria – Imported Malaria. Updated 2023.
3. RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine. N Engl J Med. 2021;384:1117‑1128.

```